PET Imaging of DHA Metabolism
NCT00074503 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85
Last updated 2017-07-02
Summary
This study will examine the use of positron emission tomography (PET) for measuring docosahexaenoic acid (DHA) absorption from the blood into the brain. DHA is a type of fatty acid found in fish and other seafood. It is involved in brain cell activity that underlies the ability to think, move, and respond to the outside world. When the amount of DHA in the brain is low, the brain may not work the same as if there were a normal amount of DHA. If PET can be used successfully to evaluate brain DHA metabolism, this method might be useful for future studies of alcoholism, since brain DHA levels are influenced by alcohol consumption.
Healthy normal volunteers between 18 and 65 years of age may be eligible for this study. Because study participants must stop taking any medications, including herbal preparations, individuals who require regular medication are excluded from this protocol. Participants will undergo the following tests and procedures:
* Psychological questionnaires concerning thoughts and behaviors.
* Nutritional status analysis: A dietitian will assess the subject's nutritional status through questionnaires and measurement of body fat. Body fat is measured using bioelectrical impedance analysis. This analysis uses a low, safe electric current to measure body composition, giving a reading of the percentage of fat in the body.
* Fat biopsy to measure the composition of fat tissue: An area on the upper half of the buttock will be numbed and a needle will be inserted to aspirate a sample of fat tissue for analysis.
* Blood drawing: Blood samples will be collected at the time of the fat biopsy and the PET scan (see below) to measure DHA and indicators that may influence DHA.
* Diet: 3 days before the fat biopsy and at least 3 days before the PET scan, subjects will consume a diet low in DHA and other omega-3 fats. This no seafood diet prohibits eating fish, shellfish, seaweed, seafood, health food products or supplemental vitamins, and foods containing canola or flaxseed oil. Caffeine-containing beverages are limited to one per day for 3 days before the study. Alcoholic beverages are prohibited for 2 weeks before the study. For 24 hours before the PET scan, subjects eat only standard meals that will be provided to them.
* Magnetic resonance imaging: A brain MRI scan will be done to fit the PET scan images onto a picture of the whole brain. During the scan, the subject lies on a table inside a narrow metal cylinder containing a strong magnetic field.
* PET scan: Before the PET scan, catheters (small plastic tubes) are inserted into an arm vein and into a wrist artery. The venous catheter is used for injecting a radioactive substance that will be detected by the scanner, and the arterial catheter is used for collecting blood samples during the scan. For the scan, the subject lies on a bed that slides into the doughnut-shaped scanner. A mask is placed to keep the head still. A transmission scan is done to see how much radiation the skull absorbs. Radioactive water (15O-water) is then injected into the blood, and the brain is scanned for about 10 minutes to measure brain blood flow. Then, radioactive DHA (11C-DHA) is injected, followed by about 1-1/2 hours of scanning to measure DHA absorption into the brain.
Conditions
- Healthy
Sponsors & Collaborators
-
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
lead NIH
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-12-12
- Completion
- 2010-07-13
Countries
- United States
Study Locations
More Related Trials
-
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease
NCT03130036 ·Status: COMPLETED ·Phase: NA
-
Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.
NCT00468806 ·Status: COMPLETED ·Phase: PHASE1
-
Brain Imaging in Elderly People and Individuals With Alzheimer's Disease
NCT00001917 ·Status: COMPLETED
-
A Brain Imaging PET Study of [11C]-Lu AF88370 in Healthy Adult Male Participants
NCT05320302 ·Status: COMPLETED ·Phase: PHASE1
-
Exploratory Positron Emission Tomography (PET) Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain
NCT00788801 ·Status: COMPLETED ·Phase: PHASE1
-
This Study Will Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers
NCT01258751 ·Status: COMPLETED ·Phase: PHASE1
-
Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II
NCT02317250 ·Status: WITHDRAWN ·Phase: PHASE3
-
Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT
NCT02815917 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
PET Imaging of P-glycoprotein Function Using [11C]dLop
NCT00605254 ·Status: COMPLETED
-
PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency
NCT00246870 ·Status: COMPLETED
-
Developing Advanced MRI Methods for Detecting the Impact of Nutrients on Infant Brain Development
NCT02058225 ·Status: COMPLETED
-
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
NCT04141150 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070
NCT03270579 ·Status: COMPLETED ·Phase: PHASE1
-
A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease
NCT01122329 ·Status: COMPLETED ·Phase: PHASE4
-
[18F]MC225-PET in Neurodegenerative Disease
NCT05853471 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Health and Aging Brain Study: Health Disparities Tau Positron Emission Tomography (PET) Scan Study
NCT05076331 ·Status: UNKNOWN
-
IGF and Other Neurotrophic Factors in Patients With Dementia
NCT02271750 ·Status: COMPLETED
-
Imaging Glutamate Release From Alcohol
NCT04159688 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis
NCT02409784 ·Status: COMPLETED ·Phase: NA
-
Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia
NCT00966017 ·Status: UNKNOWN
-
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
NCT01217021 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome Patients
NCT03977012 ·Status: UNKNOWN
-
PET Imaging of Brain Amyloid Using [11C]MeS-IMPY
NCT00407576 ·Status: COMPLETED ·Phase: PHASE1
-
Dysregulated CNS Inflammation After Acute Brain Injury
NCT03287557 ·Status: COMPLETED
-
Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers
NCT06874205 ·Status: RECRUITING ·Phase: PHASE1